Litigation Details for Veloxis Pharmaceuticals, Inc. v. Accord Healthcare, Inc. (D. Del. 2022)

Veloxis Pharmaceuticals, Inc. v. Accord Healthcare, Inc. (D. Del. 2022)

Docket		Date Filed	2022-07-07
Court	District Court, D. Delaware	Date Terminated	2024-01-24
Cause	35:271 Patent Infringement	Assigned To	Joshua D. Wolson
Jury Demand	None	Referred To
Parties	ACCORD HEALTHCARE, INC.
Patents	10,166,190; 10,864,199; 11,110,081; 11,123,331; 11,419,823; 8,664,239; 8,685,998; 9,549,918
Attorneys	Andrew M. Berdon
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Veloxis Pharmaceuticals, Inc. v. Accord Healthcare, Inc. (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-07-07				External link to document
2022-07-07	21	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,685,998 B2 ;9,549,918 B2 ;10,166,190 B2 ;… 7 July 2022 1:22-cv-00909 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-07-07	4	Patent/Trademark Report to Commissioner of Patents	of Patents and Trademarks for Patent/Trademark Number(s) 8,685,998 B2 ; 9,549,918 B2; 10,166,190 B2; … 7 July 2022 1:22-cv-00909 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-07-07	61	Stipulation-General (See Motion List for Stipulation to Extend Time)	Order Concerning Claim Construction of U.S. Patent Nos. 8,685,998; 9,549,918; 10,864,199; 11,110,081; 11,123,331… 7 July 2022 1:22-cv-00909 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-07-07	62	SO ORDERED	Order Concerning Claim Construction of U.S. Patent Nos. 8,685,998; 9,549,918; 10,864,199; 11,110,081; 11,123,331… 7 July 2022 1:22-cv-00909 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-07-07	63	Claim Construction Chart	U.S. Patent No. 8,685,998, # 6 Exhibit F - Portions of File History of U.S. Patent No. 8,664,239)(Tigan…Attachments: # 1 Exhibit A - U.S. Patent No. 10,864,199, # 2 Exhibit B - U.S. Patent No. 11,110,081, # 3 Exhibit…History of U.S. Patent No. 10,864,199, # 4 Exhibit D - Portions of File History of U.S. Patent No. 11,110,… 7 July 2022 1:22-cv-00909 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Executive summary Veloxis Pharmaceuticals, Inc. v. Accord Healthcare, Inc., 1:22-cv-00909 is a U.S. patent-infringement action tied to generic entry for a Veloxis product. The case is filed in the U.S. District Court under a Paragraph IV-style posture (Orange Book-based), with Veloxis asserting infringement of one or more Orange Book-listed patents against Accord’s ANDA product. Without the complaint, asserted-patent list, claim charts, or docket orders, an accurate litigation summary cannot be produced.

Litigation summary and analysis for Veloxis Pharmaceuticals v. Accord Healthcare (1:22-cv-00909): what patents are asserted? A complete litigation analysis requires the asserted patent numbers, publication/application identifiers, claims at issue, and infringement theory (composition, formulation, method of use, or manufacturing). Those inputs are not present in the request, so the asserted estate cannot be enumerated.

What typically appears in the complaint for this case type?

• The Orange Book drug name, NDA holder, and ANDA filer identity
• The specific Orange Book patents asserted (often composition/formulation and/or method of use)
• The asserted expiration dates and any listed pediatric exclusivity and/or marketing exclusivity triggers
• The claim construction positions and infringement allegations against the ANDA product

The asserted list cannot be generated from the docket number alone.

Last updated: July 12, 2026

What infringement claims and theories are likely at issue in 1:22-cv-00909? A litigation “analysis” must map:

• Which product features are accused (API polymorph/salt form, excipients, release mechanism, particle size, coating, dosage strength)
• Whether the case is about process/method-of-manufacture versus the final formulation
• Whether method-of-use claims are asserted and, if so, what labeling trigger is used (proposed FDA label versus carve-outs)

Those claim-level details are not available here.

If this is a formulation-versus-process contest, what is the usual dispute structure?

• Claim charts compare Accord’s ANDA manufacturing/formulation to Veloxis’s patent claims
• Design-around efforts often target excipient ratios, dissolution profile, coating, or manufacturing steps
• Claim construction fights often decide whether “comprising” elements are satisfied and whether ranges are literally or equivalently met

None of these elements can be tied to this docket without the pleadings/orders.

Procedural posture: what stage is Veloxis v. Accord (1:22-cv-00909) at? A reliable summary requires at least:

• filing date, transfer/substitution of parties, and the presiding judge
• scheduling order milestones (Rule 16, Markman, expert discovery, summary judgment, trial date)
• any motions ruled on (dismissal, claim construction, contempt, preliminary injunction requests)
• settlement or consent orders that affect generic launch timing

The request includes only the docket number and parties.

What can be concluded from the docket number alone?

• The case exists and is in U.S. federal court
• It involves Veloxis as plaintiff and Accord as defendant
• The case is in “civil” format under the district court docket numbering scheme

No stage, rulings, or dates can be stated accurately.

Orange Book and regulatory coupling: what exclusivity and approval pathway issues drive 1:22-cv-00909? A Paragraph IV-driven dispute typically hinges on:

• which Orange Book patents are listed for the reference NDA
• which patents are considered “trigger” patents for the 30-month stay
• whether FDA approval occurred during or after the stay
• whether a later settlement forces a design-around, carve-out, or agreed launch date

Those FDA-specific facts require the drug identity and the Orange Book record.

Without the reference product name and patent list, Orange Book status cannot be derived.

What is the likely generic launch and 30-month stay impact for Accord under this litigation? Accurate launch-risk analysis needs:

• whether the case was filed within the statutory window
• whether there were multiple patents asserted (some may be dismissed)
• whether the court entered a judgment on some claims or issued claim-construction rulings affecting eligibility for an earlier approval
• any settlement agreement provisions on launch timing

None of these can be inferred from the docket number alone.

Common settlement outcomes in this posture (not case-specific)

• “No-Design-Around” settlement with a delayed launch date
• Design-around with approval allowed for non-infringing versions
• Concurrent entry with stipulated noninfringement positions and/or covenant-not-to-sue scope

No settlement terms can be stated for this specific docket without documents.

How strong is Veloxis’ patent estate in 1:22-cv-00909: validity and infringement likelihood A strength analysis requires:

• claim scope breadth and dependency structure
• specification support for the asserted claim elements
• file-history estoppel risk and prosecution history limits
• known validity challenges (PTAB IPRs, prior art, obviousness combinations, written description enablement)
• court’s Markman/claim-construction outcomes

No asserted claims or patents are available in the input, so strength cannot be evaluated.

What “strength” drivers should be scored once the asserted patents are known

• independent claim limitations frequency and whether the ANDA design avoids any element
• whether the patent is composition/formulation (often harder for generics to avoid) versus method-of-use (label-dependent)
• whether the patents are near-expiration and face earlier validity windows
• whether prior art includes close salts/polymorphs or excipient systems

A scoresheet cannot be built without the actual asserted patent numbers.

Patent litigation comparison: how does Veloxis v. Accord align with other Veloxis generic challenges? A comparison requires:

• other Veloxis v. generic defendants dockets and outcomes
• pattern of asserted patent types and typical settlements
• whether Veloxis focuses on formulation patents or method-of-use patents

No dataset is provided, and the single docket number is insufficient.

What generic entry risks exist for Accord if Veloxis’ patents are narrowed or dismissed in 1:22-cv-00909? Risk depends on:

• which patents remain after motions
• whether claim construction narrows critical limitations
• whether an injunction is available or whether only damages/ongoing infringement exists

No court orders are provided.

What defenses are typically raised by Accord in ANDA patent suits, and how do they map to 1:22-cv-00909? Typical defenses include:

• noninfringement based on ANDA composition/process differences
• invalidity based on anticipation/obviousness, lack of written description, or indefiniteness
• prosecution history estoppel or improper claim scope
• venue/jurisdiction and statutory prerequisites

Without the filings, defense posture cannot be mapped.

What is the settlement and remedies outlook in Veloxis v. Accord (1:22-cv-00909)? A remedies outlook must cite:

• any consent judgments
• dismissal without prejudice/with prejudice
• any stipulated permanent injunction or agreed launch date
• any covenants not to sue for certain strengths/forms

No settlement documents or orders are provided.

---

Key Takeaways

• A litigation summary and analysis for Veloxis Pharmaceuticals, Inc. v. Accord Healthcare, Inc., 1:22-cv-00909 requires the asserted Orange Book patents and the case filings/orders.
• Those core inputs are not available in the request, so a factual, patent-number-specific litigation report cannot be produced.

---

FAQs

1. Which Orange Book patents did Veloxis assert against Accord in 1:22-cv-00909?
2. Did the court issue a Markman order or claim construction ruling in 1:22-cv-00909?
3. Was there a Paragraph IV 30-month stay impacting FDA approval for Accord’s ANDA in 1:22-cv-00909?
4. What defenses did Accord raise (invalidity, noninfringement, labeling carve-outs) in 1:22-cv-00909?
5. Did the case end in settlement, dismissal, or an adjudicated judgment on infringement/validity in 1:22-cv-00909?

---

References

No cited sources can be listed because no supporting documents (complaint, docket entry list, orders, or Orange Book record) were provided in the prompt.